PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
OBJECTIVE
In a previous study, the authors found that reduced expression of peroxisome proliferator-activated receptor (PPAR)-alpha might play an important role in developing nonalcoholic fatty liver disease (NAFLD). The aim of this study was to analyze the effects of PPAR-alpha and -gamma agonists on NAFLD and verify the mechanisms underlying the PPAR-alpha and -gamma agonist-induced improvements by evaluating the hepatic gene expression profile involved in fatty-acid metabolism, using the Otsuka-Long Evans-Tokushima fatty (OLETF) rat.


METHODS
Rats were assigned to a control group (group I), fatty liver group (group II), PPAR-alpha agonist treatment group (group III), or PPAR-gamma agonist treatment group (group IV). Fasting blood glucose, total cholesterol, and triglycerides were measured. Liver tissues from each group were processed for histological and gene expression analysis. mRNAs of enzymes involved in fatty-acid metabolism and tumor necrosis factor (TNF)-alpha were measured.


RESULTS
After 28 weeks treatment with PPAR-alpha or -gamma agonist, steatosis of the liver was improved in groups III and IV compared with group II. Fasting blood glucose levels were significantly lower in groups III and IV than in group II. In group III, mRNA expression of fatty-acid beta-oxidation enzymes, such as fatty-acid transport protein (FATP), fatty-acid binding protein, carnitine palmitoyltransferase II, medium-chain acyl-CoA dehydrogenase (MCAD), long-chain acyl-CoA dehydrogenase, and acyl-CoA oxidase, was significantly increased. However, the treatment-induced modulation of fatty-acid beta-oxidation enzymes was confined to FATP and MCAD in group IV. TNF-alpha tended to be reduced in groups III and IV compared with group II.


CONCLUSIONS
Treatment with PPAR agonists, especially a PPAR-alpha agonist, improved the histological and biochemical parameters in the OLETF rat model by inducing fatty-acid metabolic enzymes.
Seo
Yeon Seok
YS
Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, Korea.
Kim
Ji Hoon
JH
Jo
Nam Young
NY
Choi
Kyung Mook
KM
Baik
Sei Hyun
SH
Park
Jong-Jae
JJ
Kim
Jae Seon
JS
Byun
Kwan Soo
KS
Bak
Young-Tae
YT
Lee
Chang Hong
CH
Kim
AeRee
A
Yeon
Jong Eun
JE
D000818:Animals; D004195:Disease Models, Animal; D005227:Fatty Acids / Q000378:metabolism; D005234:Fatty Liver / Q000188:drug therapy*; D011345:Fenofibrate / Q000494:pharmacology / Q000627:therapeutic use; D020869:Gene Expression Profiling; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects / Q000235:genetics*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D047493:PPAR alpha / Q000819:agonists; D047495:PPAR gamma / Q000819:agonists; D051381:Rats; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use
D005227:Fatty Acids; D000960:Hypolipidemic Agents; D047493:PPAR alpha; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D011345:Fenofibrate